Novo Nordisk presents phase 3 data for next generation amylin cagrilintide, leading to advancement into dedicated clinical programme Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications